|
C3ORF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
9.59589999682819E-08 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
3.605600E-01 |
| Stage1-vs-Stage3 |
1.713610E-02 |
| Stage1-vs-Stage4 |
1.060430E-03 |
| Stage2-vs-Stage3 |
2.191900E-02 |
| Stage2-vs-Stage4 |
1.482230E-03 |
| Stage3-vs-Stage4 |
2.046600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
6.5842997720722E-10 |
| Normal-vs-Asian |
5.21882537185547E-12 |
| Caucasian-vs-AfricanAmerican |
3.539400E-01 |
| Caucasian-vs-Asian |
8.463400E-01 |
| AfricanAmerican-vs-Asian |
3.065000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.615420E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
2.44249065417534E-15 |
| Normal-vs-Age(61-80Yrs) |
2.29805063867161E-12 |
| Normal-vs-Age(81-100Yrs) |
3.048000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.164200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.075600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.223800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.541000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.054200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.595800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.412100E-04 |
| Classical-VS-Follicular |
1.652280E-02 |
| Classical-VS-Other |
9.747200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
4.76540000005077E-06 |
| Tall-VS-Other |
4.261400E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.410800E-01 |
| Follicular-VS-Normal |
8.17730000379768E-08 |
| Other-VS-Normal |
6.628900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.40110145707695E-13 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
1.175070E-03 |
|
|
